Phibro Animal Health Financial Results
Phibro Animal Health reported Q1 2027 net sales of $386.8 million, a 6% increase year-over-year, driven by growth in Mineral Nutrition and Performance Products. The company maintained its full-year fiscal 2027 guidance despite regulatory headwinds for virginiamycin in Brazil. Additionally, shareholders ratified the election of three Class I directors and the appointment of PwC as auditors at the annual meeting.
- Term
- Q1 2027
“First quarter results exceeded our expectations and grew on top of a strong first quarter last year. The outperformance was led largely by a strong start to the year in Mineral Nutrition and Performance Products while our core Animal Health business delivered sales in line with our plan and Adjusted EBITDA ahead of plan, including the benefit of certain costs that shifted into the second quarter.”
Dani Bendheim, President and Chief Executive Officer
“Improving working capital and cash conversion is a top priority, and we are committed to delivering meaningful progress during fiscal 2027.”
Dani Bendheim, President and Chief Executive Officer